Edition:
United States

Novus Therapeutics Inc (NVUS.OQ)

NVUS.OQ on NASDAQ Stock Exchange Capital Market

4.21USD
3:59pm EST
Change (% chg)

$-0.09 (-2.21%)
Prev Close
$4.30
Open
$4.27
Day's High
$4.33
Day's Low
$4.21
Volume
636
Avg. Vol
3,418
52-wk High
$15.12
52-wk Low
$3.42

Latest Key Developments (Source: Significant Developments)

Novus Therapeutics Inc reported Q3 $0.43 loss per share​
Wednesday, 8 Nov 2017 05:17pm EST 

Nov 8 (Reuters) - Novus Therapeutics Inc :Novus Therapeutics Inc - ‍for Q3 of 2017, Novus reported $0.43 loss per share​.  Full Article

Novus Therapeutics reports third quarter 2017 results
Wednesday, 8 Nov 2017 04:53pm EST 

Nov 8 (Reuters) - Novus Therapeutics Inc :Novus Therapeutics reports third quarter 2017 results.Q3 loss per share $0.43.  Full Article

Novus Therapeutics reports Q2 loss per share $1.32
Wednesday, 9 Aug 2017 08:15pm EDT 

Aug 10 (Reuters) - Novus Therapeutics Inc -:Novus Therapeutics reports second quarter 2017 results.Q2 loss per share $1.32.  Full Article

Ran Nussbaum reports 11.3 pct passive stake in Novus Therapeutics as of May 9
Thursday, 25 May 2017 05:38pm EDT 

May 25 (Reuters) - Novus Therapeutics Inc :Ran nussbaum reports 11.3 percent passive stake in novus therapeutics inc as of may 9, 2017 - sec filing.  Full Article

Peregrine Ventures Management reports 8.9 percent passiave stake in Novus Therapeutics as of May 9
Monday, 22 May 2017 02:53pm EDT 

May 22 (Reuters) - Peregrine Ventures Management Ltd :Peregrine Ventures Management Ltd reports a 8.9 percent passiave stake in Novus Therapeutics Inc as of May 9, 2017 - sec filing.  Full Article

Tokai pharmaceuticals inc says under terms of deal co may be required to pay Otic termination fee of $1 million
Thursday, 22 Dec 2016 09:42am EST 

Tokai Pharmaceuticals Inc :Tokai Pharmaceuticals Inc says co may be required to pay Otic a termination fee of $1 million, or Otic may be required to pay co termination fee of $1.5 million.  Full Article

Tokai Pharmaceuticals and Otic Pharma enter into share purchase deal
Thursday, 22 Dec 2016 08:00am EST 

Tokai Pharmaceuticals Inc : Tokai Pharmaceuticals and Otic Pharma enter into share purchase agreement . Tokai Pharmaceuticals Inc says upon exchange, it is expected that existing tokai stockholders will own approximately 40% of combined company . Tokai Pharmaceuticals - entered into a definitive share purchase agreement under which shareholders of otic pharma will become majority owners of tokai . Tokai Pharmaceuticals Inc - gregory j. Flesher to be named president and chief executive officer of combined company . Tokai Pharmaceuticals Inc - shareholders of otic pharma will receive a total of 32.2 million shares of newly issued tokai common stock . Transaction has been unanimously approved by boards of directors of both companies and shareholders of otic pharma . Tokai Pharmaceuticals Inc says existing otic pharma shareholders owning approximately 60% of combined company . Tokai Pharmaceuticals - upon close of transaction, board of combined cowill consist of 7 members, 3 to be designated by tokai, 4 to be designated by otic pharma .Tokai Pharmaceuticals - an otic pharma investor syndicate has committed to invest $7 million of additional capital in connection with share purchase agreement.  Full Article

Tokai Pharmaceuticals appoints John S. Mcbride CFO
Wednesday, 3 Aug 2016 07:54am EDT 

Tokai Pharmaceuticals Inc : Lee H. Kalowski, chief financial officer will cease employment effective august 31, 2016 - SEC filing . CFO, EVP, business operations and general counsel, will cease employment in relation to previously announced workforce reduction . Previously announced retirement of Karen J. Ferrante, chief medical officer, will become effective on august 31, 2016 .Appointed John S. Mcbride chief financial officer effective September 1, 2016.  Full Article

Tokai Pharmaceuticals says reducing workforce by about 60 pct
Friday, 29 Jul 2016 04:05pm EDT 

Tokai Pharmaceuticals Inc : Tokai pharmaceuticals announces reduction in force . Workforce reduction plan expected to be largely completed by end of q3 of 2016. . Says expects reduction in force to result in approximately $4.2 million in reduced annualized operating expenses . Also expects to incur a charge in q3 of 2016 of approximately $1.3 million related to reduction . Reducing its workforce by approximately 60 percent, to a total of 10 full-time equivalent employees . Says reducing its workforce by approximately 60 percent, to a total of 10 full-time equivalent employees . Says reduction plan expected to be largely completed by end of q3 of 2016 .Says also expects to incur a charge in q3 of 2016 of approximately $1.3 million related to reduction, including severance.  Full Article

Tokai Pharmaceuticals posts Q1 loss per share $0.51
Tuesday, 10 May 2016 07:15am EDT 

Tokai Pharmaceuticals Inc : Tokai Pharmaceuticals reports first quarter 2016 financial results . Q1 loss per share $0.51 .Q1 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Novus Therapeutics Inc reported Q3 $0.43 loss per share​

* Novus Therapeutics Inc - ‍for Q3 of 2017, Novus reported $0.43 loss per share​ Source text: (http://bit.ly/2hldAkp) Further company coverage: